RO6953958

RO6953958 is an experimental small molecule drug developed by Hoffmann-La Roche as a potent and selective antagonist of the human vasopressin V1a receptor. By blocking the activation of this G protein-coupled receptor in the brain, RO6953958 aims to modulate neural pathways involved in circadian rhythm and social behavior. Preclinical evidence suggests that antagonism of the V1a receptor may accelerate resynchronization of circadian rhythms, potentially improving sleep/wake cycles and addressing social deficits associated with neurodevelopmental disorders (NDDs), including autism spectrum disorder. The drug has been evaluated in Phase 1 clinical trials for its safety, tolerability, pharmacokinetics, pharmacodynamics, food effect, and potential for drug-drug interactions in healthy volunteers.